Veeva Systems Inc. — Form 10-Q Summary
Reporting period: Three months ended April 30, 2024 (Veeva fiscal first quarter of 2025). Veeva provides cloud software, data, analytics, professional services and consulting, primarily for life sciences.
Financial performance
| Metric | Q1 FY2025 | Prior-year quarter | Change |
|---|---|---|---|
| Total revenue | $650.3 million | $526.3 million | +24% |
| Subscription revenue | $534.0 million | $414.5 million | +29% |
| Professional services and other revenue | $116.4 million | $111.8 million | +4% |
| Gross profit / gross margin | $476.5 million / 73% | $359.7 million / 68% | +32% profit |
| Operating income / operating margin | $155.2 million / 24% | $61.5 million / 12% | +152% income |
| Net income | $161.7 million | $131.5 million | +23% |
| Diluted EPS | $0.98 | $0.81 | +21% |
| Operating cash flow | $763.5 million | $505.9 million | +51% |
R&D Solutions subscription revenue was $272.6 million, up from $175.2 million; Commercial Solutions subscription revenue was $261.3 million, up from $239.3 million. R&D accounted for 51% of subscription revenue this quarter. North America generated $381.6 million of total revenue, Europe $189.9 million, Asia Pacific $62.4 million, and Middle East, Africa and Latin America $16.4 million.
Financial position and liquidity
- At April 30, 2024, cash and cash equivalents were $1.20 billion and short-term investments were $3.57 billion, totaling approximately $4.76 billion. Cash, cash equivalents and short-term investments held outside the U.S. included $85 million of cash and cash equivalents.
- Total assets were $6.19 billion; total liabilities were $1.30 billion; stockholders’ equity was $4.89 billion. The balance sheet reports no borrowings or other funded debt. Lease liabilities totaled $55.7 million.
- Cash and cash equivalents increased by $493.7 million during the quarter. Investing activities used $272.4 million, primarily for net purchases of short-term investments; financing activities provided $3.8 million.
- Operating cash flow is seasonally strongest in the first fiscal quarter due to annual subscription billings and collections. Management expects cash flow from operations to be substantially lower in later quarters. It also expects FY2025 cash taxes related to federal R&D capitalization rules to reduce operating cash flow.
Changes, outlook and management commentary
- Revenue growth was led by subscription services, which contributed $119 million of the $124 million year-over-year revenue increase. R&D Solutions contributed $97 million of subscription growth and Commercial Solutions $22 million.
- Gross margin improved to 73% from 68%. Subscription gross margin was 85%, versus 84%; professional services gross margin was 18%, versus 11%. Management cited lower use of third-party services as a factor in professional services cost performance.
- Operating income growth outpaced revenue growth. Operating expenses rose 8% overall: R&D increased 11%, sales and marketing 10%, while general and administrative expense declined 2%.
- Other income increased to $51.7 million from $30.2 million, mainly reflecting higher interest income from larger investment balances and higher rates. The effective tax rate was 21.9%, compared with a 43.3% tax benefit rate in the prior-year quarter; the difference primarily reflected lower excess tax benefits from equity compensation in the current period.
- Management expects FY2025 revenue growth to accelerate versus FY2024, partly because FY2024 was affected by a contracting change that altered revenue timing. The filing provides no specific revenue guidance figures in the text supplied. Management expects operating expenses to increase in FY2025, primarily due to employee compensation; near-term subscription costs may also rise with usage and data costs.
- Stock-based compensation was $95.9 million for the quarter, a significant non-cash expense. Non-GAAP diluted EPS was $1.50 versus $0.91; this measure excludes stock compensation, purchased-intangible amortization and a $5 million litigation settlement, among other adjustments. Non-GAAP measures are not substitutes for GAAP results.
- Remaining performance obligations for non-cancellable subscription contracts longer than one year were not significant; most allocated transaction price was included in deferred revenue and expected to be recognized within 12 months.
Risks, contingencies and unusual items
- IQVIA litigation: IQVIA’s trade-secret claims are scheduled for trial beginning February 10, 2025; no trial date is set for Veeva’s antitrust claims. Veeva says it cannot estimate a probable loss or gain. Its counterclaims seek injunctive relief and damages exceeding $200 million, which are not assured. Partial contingency-fee arrangements have not been accrued because the liability cannot be estimated.
- Mednet litigation: Veeva entered a settlement agreement on May 30, 2024, after quarter-end, expected to result in dismissal with prejudice. The filing identifies a $5 million litigation settlement adjustment but does not clearly quantify the settlement payment in the supplied text.
- Competition and CRM transition: Salesforce and IQVIA announced an expanded CRM partnership in April 2024. Veeva plans to migrate CRM customers from Salesforce’s platform to Vault CRM and does not intend to renew its Salesforce platform agreement when it expires September 1, 2025. Migration execution, customer retention and service continuity are key risks.
- Investment and currency exposure: A 100-basis-point immediate interest-rate increase would reduce the estimated market value of the investment portfolio by $45 million; a 100-basis-point decrease would increase it by the same amount. Unrealized investment losses were reflected in other comprehensive income. Foreign-exchange exposure remains, although realized and unrealized foreign-currency losses were immaterial in the quarter.
- Other principal risks include cybersecurity or service disruptions, reliance on third-party infrastructure and data providers, privacy and regulatory changes, life-sciences industry conditions, customer concentration, and pressure on renewals or adoption of newer products. Management states liquidity should be sufficient for working capital and capital needs for at least the next 12 months.
Most important facts for investors to verify
- Whether subscription growth, particularly in R&D Solutions, continues and whether management’s FY2025 acceleration outlook is supported by subsequent results.
- Whether the improved gross and operating margins persist as headcount, infrastructure use and data costs increase; assess the impact of stock-based compensation on reported profitability.
- How much operating cash flow falls after the seasonally strong first quarter, including the effect of expected cash taxes.
- Progress, customer adoption and costs of the Vault CRM transition, and competitive impact from the Salesforce–IQVIA partnership.
- Developments in the IQVIA trial and Mednet settlement, including any eventual financial exposure not quantifiable in this filing.
- Investment portfolio valuation and rate sensitivity, and whether renewal, customer concentration, privacy and cybersecurity risks change materially.